Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


02.05.2022

1 AJR Am J Roentgenol
4 Am J Gastroenterol
3 Biochem Biophys Res Commun
1 BMC Cancer
3 BMC Gastroenterol
3 Br J Surg
1 Dig Dis Sci
2 Endoscopy
5 Eur Radiol
3 Gastroenterology
2 Gut
13 Hepatology
4 Int J Cancer
2 J Comput Assist Tomogr
1 J Gastroenterol
11 J Hepatol
3 J Pediatr
2 Oncogene
5 PLoS One
1 Radiol Imaging Cancer


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. LIU PS
    Editorial Comment: Is Quantitative CT Fat Fraction Ready For Prime Time?
    AJR Am J Roentgenol. 2021 Dec 15. doi: 10.2214/AJR.21.27184.
    PubMed        


    Am J Gastroenterol

  2. LEE HL, Lin MC, Yeh FC, Tsai MK, et al
    Klebsiella pneumoniae Invasive Syndrome With Ventriculitis.
    Am J Gastroenterol. 2022;117:372.
    PubMed        

  3. DUARTE-ROJO A, Sejdic E
    Artificial Intelligence and the Risk for Intuition Decline in Clinical Medicine.
    Am J Gastroenterol. 2022;117:401-402.
    PubMed         Abstract available

  4. ZHAO Y, Li X, Yang S, Tao Y, et al
    Small-Diameter Drug-Eluting Beads-Based Transarterial Chemoemboli-zation (DEB-TACE) for Treating Patients With Esophageal Cancer With Acute Bleeding.
    Am J Gastroenterol. 2022 Feb 8. pii: 00000434-990000000-00244.
    PubMed        

  5. VIEIRA BARBOSA J, Milligan S, Frick A, Broestl J, et al
    Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease.
    Am J Gastroenterol. 2022;117:453-461.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  6. EL-ASHMAWY NE, Khedr NF, Sallam M, Nossier AI, et al
    Effect of activation of liver X receptor alpha on cardiac & hepatic ABCC10 and SLC17A5 drug transporters in hypercholesterolemic rat model.
    Biochem Biophys Res Commun. 2022;610:133-139.
    PubMed         Abstract available

  7. OH HA, Kim YJ, Moon KS, Seo JW, et al
    Identification of integrative hepatotoxicity induced by lysosomal phospholipase A2 inhibition of cationic amphiphilic drugs via metabolomics.
    Biochem Biophys Res Commun. 2022;607:1-8.
    PubMed         Abstract available

  8. FAN K, Zan X, Zhi Y, Yang Y, et al
    Immune response gene 1 deficiency impairs Nrf2 activation and aggravates liver fibrosis in mice.
    Biochem Biophys Res Commun. 2022;607:103-109.
    PubMed         Abstract available


    BMC Cancer

  9. LUAN H, He Y, Zhang T, Su Y, et al
    The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma.
    BMC Cancer. 2022;22:463.
    PubMed         Abstract available


    BMC Gastroenterol

  10. ZHU W, Liang A, Shi P, Yuan S, et al
    Higher serum uric acid to HDL-cholesterol ratio is associated with onset of non-alcoholic fatty liver disease in a non-obese Chinese population with normal blood lipid levels.
    BMC Gastroenterol. 2022;22:196.
    PubMed         Abstract available

  11. KARAM E, Bucur P, Gil C, Sindayigaya R, et al
    Simultaneous or staged resection for synchronous liver metastasis and primary rectal cancer: a propensity score matching analysis.
    BMC Gastroenterol. 2022;22:201.
    PubMed         Abstract available

  12. CHI X, Jiang L, Yuan Y, Huang X, et al
    A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China.
    BMC Gastroenterol. 2022;22:202.
    PubMed         Abstract available


    Br J Surg

  13. CRISTAUDO AT, Morris DL
    Hypothesis to explain the disparity in the proportion of liver metastases between appendiceal and colorectal cancer.
    Br J Surg. 2022 Feb 8. pii: 6524033. doi: 10.1093.
    PubMed        

  14. SIRIWARDENA AK
    Synchronous resection of primary colorectal cancer with liver metastases: two birds with one stone?
    Br J Surg. 2022 Feb 3. pii: 6521658. doi: 10.1093.
    PubMed        

  15. RAMOUZ A, Ali-Hasan-Al-Saegh S, Shafiei S, Fakour S, et al
    Repeat liver resection for recurrent intrahepatic cholangiocarcinoma: meta-analysis.
    Br J Surg. 2022 Apr 28. pii: 6575275. doi: 10.1093.
    PubMed         Abstract available


    Dig Dis Sci

  16. B HADI Y, Khan RS, Lakhani DA, Khan AY, et al
    Antibiotic Prophylaxis for Upper Gastrointestinal Bleed in Liver Cirrhosis; Less May Be More.
    Dig Dis Sci. 2022 Apr 25. pii: 10.1007/s10620-022-07481.
    PubMed         Abstract available


    Endoscopy

  17. YONAMINE K, Koshita S, Kanno Y, Ogawa T, et al
    Endoscopic ultrasound (EUS)-guided antegrade intervention for a hepaticojejunostomy anastomosis obstruction under peroral cholangioscopy via an EUS-guided hepaticogastrostomy route.
    Endoscopy. 2022 Apr 25. doi: 10.1055/a-1810-7068.
    PubMed        

  18. GARCIA-SUMALLA A, Maisterra S, Amador-Navarrete A, Castellote J, et al
    Nonadhesive massive coiling endoscopic ultrasound-guided embolization in a single session for treatment of gastric varices: learning points of a technical variant.
    Endoscopy. 2022;54:E228-E229.
    PubMed        


    Eur Radiol

  19. HEO S, Kim DW, Choi SH, Kim SW, et al
    Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis.
    Eur Radiol. 2022;32:3377-3387.
    PubMed         Abstract available

  20. SHIN J, Lee S, Hwang JA, Lee JE, et al
    MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis.
    Eur Radiol. 2022;32:3319-3326.
    PubMed         Abstract available

  21. TANG A, Dzyubak B, Yin M, Schlein A, et al
    MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T.
    Eur Radiol. 2022;32:2937-2948.
    PubMed         Abstract available

  22. PARK S, Yoon JH, Joo I, Yu MH, et al
    Image quality in liver CT: low-dose deep learning vs standard-dose model-based iterative reconstructions.
    Eur Radiol. 2022;32:2865-2874.
    PubMed         Abstract available

  23. GHADIMI M, Birnbaum J, Kamel IR, Sirlin CB, et al
    What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
    Eur Radiol. 2022;32:3327-3333.
    PubMed         Abstract available


    Gastroenterology

  24. GAN W, Liao B, Li X
    A Rare Cause of Liver Fibrosis in Adulthood.
    Gastroenterology. 2022;162:e1-e3.
    PubMed        

  25. GOUDSMIT BFJ, Putter H, Van Hoek B
    The Model for End-Stage Liver Disease 3.0: An Update Without Proven Accuracy.
    Gastroenterology. 2022;162:1781-1782.
    PubMed        

  26. DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
    The Negative Bidirectional Interaction Between Climate Change and the Prevalence and Care of Liver Disease: A Joint BSG, BASL, EASL, and AASLD Commentary.
    Gastroenterology. 2022;162:1561-1567.
    PubMed        


    Gut

  27. HERNAEZ R, Avila MA
    Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
    Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.
    PubMed        

  28. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
    PubMed        


    Hepatology

  29. CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;75:1071-1072.
    PubMed        

  30. YAN T, Luo Y, Yan N, Hamada K, et al
    Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
    Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
    PubMed         Abstract available

  31. SHAH PA, Patil R, Harrison SA
    NAFLD-related hepatocellular carcinoma: The growing challenge.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
    PubMed         Abstract available

  32. REN QN, Zhang H, Sun CY, Zhou YF, et al
    Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
    Hepatology. 2022;75:1123-1138.
    PubMed         Abstract available

  33. SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
    Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
    Hepatology. 2022;75:1026-1037.
    PubMed         Abstract available

  34. SONG J, Song H, Wei H, Sun R, et al
    Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
    Hepatology. 2022;75:1181-1193.
    PubMed         Abstract available

  35. ZHANG JL, Du BB, Zhang DH, Li H, et al
    OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
    Hepatology. 2022;75:1218-1234.
    PubMed         Abstract available

  36. KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
    Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
    Hepatology. 2022;75:1139-1153.
    PubMed         Abstract available

  37. PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
    Global burden of NAFLD and chronic liver disease among adolescents and young adults.
    Hepatology. 2022;75:1204-1217.
    PubMed         Abstract available

  38. ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
    Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;75:1289-1299.
    PubMed         Abstract available

  39. CHUNG HH
    Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
    Hepatology. 2022;75:1338-1339.
    PubMed        

  40. LEE CH, Lui DTW, Lam KSL
    Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
    Hepatology. 2022;75:1340.
    PubMed        

  41. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
    Fontan-associated liver disease.
    Hepatology. 2022;75:1300-1321.
    PubMed        


    Int J Cancer

  42. LIAO W, Du J, Wang Z, Feng Q, et al
    The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34040.
    PubMed         Abstract available

  43. CHEN S, Gao Y, Wang Y, Daemen T, et al
    The Combined Signatures of Hypoxia and Cellular Landscape Provides a Prognostic and Therapeutic Biomarker in HBV-Related Hepatocellular Carcinoma.
    Int J Cancer. 2022 Apr 25. doi: 10.1002/ijc.34045.
    PubMed         Abstract available

  44. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    PubMed         Abstract available

  45. YUN J, Kim YS, Heo MJ, Kim MJ, et al
    ERalpha inhibits mesenchymal and amoeboidal movement of liver cancer cell via Galpha12.
    Int J Cancer. 2022;150:1690-1705.
    PubMed         Abstract available


    J Comput Assist Tomogr

  46. SIM KC, Kim MJ, Cho Y, Kim HJ, et al
    Diagnostic Feasibility of Magnetic Resonance Elastography Radiomics Analysis for the Assessment of Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    J Comput Assist Tomogr. 2022 Apr 27. pii: 00004728-990000000-00026.
    PubMed         Abstract available

  47. LEE CM, Kang BK, Kim M
    Differentiation of Small Hepatic Abscess From Hepatic Metastasis With a Combination of Imaging Parameters.
    J Comput Assist Tomogr. 2022 Apr 26. pii: 00004728-990000000-00023.
    PubMed         Abstract available


    J Gastroenterol

  48. IRITANI S, Kawamura Y, Muraishi N, Fujiyama S, et al
    The useful predictors of zinc deficiency for the management of chronic liver disease.
    J Gastroenterol. 2022;57:322-332.
    PubMed         Abstract available


    J Hepatol

  49. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    PubMed         Abstract available

  50. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    PubMed         Abstract available

  51. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    PubMed        

  52. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    PubMed         Abstract available

  53. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    PubMed         Abstract available

  54. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    PubMed         Abstract available

  55. LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
    The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
    J Hepatol. 2022;76:771-780.
    PubMed         Abstract available

  56. BYRNE CD, Newsome PN, Noureddin M
    Why are there no strategies for NAFLD?
    J Hepatol. 2022;76:763-764.
    PubMed        

  57. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    PubMed         Abstract available

  58. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    PubMed        

  59. MEHAL WZ, Schwabe RF
    A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:765-767.
    PubMed        


    J Pediatr

  60. OVCHINSKY N, Litman N
    50 Years Ago in TheJournalofPediatrics: Disappearance of Reye Syndrome Outbreaks: One of the Greatest Public Health Victories.
    J Pediatr. 2022;243:207.
    PubMed        

  61. MCLEAN MA, Scoten OC, Yu W, Ye XY, et al
    Lower Maternal Chronic Physiological Stress and Better Child Behavior at 18 Months: Follow-Up of a Cluster Randomized Trial of Neonatal Intensive Care Unit Family Integrated Care.
    J Pediatr. 2022;243:107-115.
    PubMed         Abstract available

  62. SONG K, Park G, Lee HS, Lee M, et al
    Comparison of the Triglyceride Glucose Index and Modified Triglyceride Glucose Indices to Predict Nonalcoholic Fatty Liver Disease in Youths.
    J Pediatr. 2022;242:79-85.
    PubMed         Abstract available


    Oncogene

  63. CHEN J, Li Z, Jia X, Song W, et al
    Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity.
    Oncogene. 2022 Apr 27. pii: 10.1038/s41388-022-02274.
    PubMed         Abstract available

  64. TSAI YT, Li CY, Huang YH, Chang TS, et al
    Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts.
    Oncogene. 2022 Apr 22. pii: 10.1038/s41388-022-02309.
    PubMed         Abstract available


    PLoS One

  65. FU J, Gao Y, Shi L
    Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0267647.
    PubMed         Abstract available

  66. ISHII M, Itano O, Morinaga J, Shirakawa H, et al
    Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    PLoS One. 2022;17:e0266707.
    PubMed         Abstract available

  67. GAIRING SJ, Galle PR, Schattenberg JM, Kostev K, et al
    Portal vein thrombosis is associated with an increased risk of bone fractures.
    PLoS One. 2022;17:e0267535.
    PubMed         Abstract available

  68. NGUYEN TB, Do DN, Nguyen TTP, Nguyen TL, et al
    Immune-related biomarkers shared by inflammatory bowel disease and liver cancer.
    PLoS One. 2022;17:e0267358.
    PubMed         Abstract available

  69. CHEN PC, Lee YC, Su YC, Lee CH, et al
    Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan.
    PLoS One. 2022;17:e0266960.
    PubMed         Abstract available


    Radiol Imaging Cancer

  70. SHAH RP, Laeseke PF, Shin LK, Chin FT, et al
    Limitations of Fluorine 18 Fluoromisonidazole in Assessing Treatment-induced Tissue Hypoxia after Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Prospective Pilot Study.
    Radiol Imaging Cancer. 2022;4:e210094.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: